Reata to Present at BMO Capital Markets Healthcare Conference

Presentation Scheduled for Wednesday, August 6 at 9:00 EST

IRVING, TX -- July 28, 2008 -- Reata Pharmaceuticals, Inc. announces that its CEO, Warren Huff, will be presenting a company overview on Wednesday, August 6, 2008 at the BMO Capital Markets "Focus on Healthcare Conference" at 9:00 a.m., Eastern Time. The event is being held at the Milennium Broadway Hotel in New York, New York.

The company review will highlight clinical data on RTA 402, an orally available, first-in-class Antioxidant Inflammation Modulator (AIM) in Phase 2 development for diabetic nephropathy and cancer. Mr. Huff will also share data on other AIMs advancing through preclinical development for other indications, including multiple sclerosis, COPD, and neurodegenerative diseases. Each of these drugs targets areas of substantial unmet medical need and has significant commercial potential.

An update will also be provided on berubicin (also known as RTA 744), a novel anthracycline in Phase 2 development for brain metastases. Lastly, Mr. Huff will provide an update on the progress the company has made in identifying small molecule drugs that correct protein misfolding. Using Reata's best-in-class assay, the company has succeeded in identifying a small molecule drug that rescues the misfolded SOD1, a protein implicated in the development of amyotrophic lateral sclerosis, known more commonly as Lou Gehrig's disease.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. The company's two lead programs are in advanced clinical trials for chronic kidney disease and cancer. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform based around the use of small molecule molecular chaperones to correct protein misfolding. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com.

845-635-9828

kathryn@kmorrispr.com